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As countries decide on vaccination strategies and how to ease movement 
restrictions, estimating the proportion of the population previously infected with 
SARS-CoV-2 is important for predicting the future burden of COVID-19. This 
proportion is usually estimated from serosurvey data in two steps: first the proportion 
above a threshold antibody level is calculated, then the crude estimate is adjusted 
using external estimates of sensitivity and specificity. A drawback of this approach is 
that the PCR-confirmed cases used to estimate the sensitivity of the threshold may 
not be representative of cases in the wider population—e.g. they may be more 
recently infected and more severely symptomatic.  Mixture modelling offers an 
alternative approach that does not require external data from PCR-confirmed cases. 
Here we illustrate the bias in the standard threshold-based approach by comparing 
both approaches using data from several Kenyan serosurveys.  We show that the 
mixture model analysis produces estimates of previous infection that are often 
substantially higher than the standard threshold analysis.   
 
Introduction 
Establishing the amount of previous infection with SARS-CoV-2 is key to predicting 
the future impact of the virus. The evidence to date suggests that reinfection is 
uncommon, at least in the short term, and associated with mild disease 1,2. 
Therefore, knowing how many people have previously been infected can help to 
establish to what extent a population is protected by natural infection. 
 
 
The proportion previously infected is usually estimated from serological surveys (i.e. 
data on antibody levels). The conventional analysis of these data involves estimating 
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the proportion above an arbitrary threshold and adjusting for the sensitivity and 
specificity at that threshold 3,4. However, sensitivity is usually estimated using 
samples from PCR-positive cases who are symptomatic and have been recently 
infected. Since these samples typically have higher antibody levels than samples 
from the general population of previously infected individuals, including those with 
asymptomatic infection, this may lead to the overestimation of sensitivity and 
underestimation of the proportion previously infected 5. Bias of this kind, that is bias 
that arises because sensitivity (or specificity) is estimated in a non-representative 
sample, is often referred to as spectrum bias.  Mixture models offer an alternative 
approach to the analysis of serological data that does not involve specifying a 
threshold and is therefore not vulnerable to spectrum bias 6,7. 
 
In this paper, we use data on antibody concentrations—optical density (OD) ratios 
measured by ELISA—from several Kenyan SARS-CoV-2 serosurveys to compare 
the standard threshold-based analysis with a mixture modelling approach.  
In the mixture model, we assume the observed distribution of antibody levels is a 
mixture of two unobserved distributions—the distribution in individuals who have 
experienced previous infection and the distribution in those who have not. The model 
is therefore characterised by the two component distributions and the proportion in 
each component. For the uninfected component we specify that log antibody 
concentrations follow a normal distribution, and for the infected component we 
specify they follow a skew normal distribution 7. To fit the model, we fix the variance 
of the uninfected component at a value estimated from pre-COVID-19 samples, and 
estimate the remaining parameters using a Markov chain Monte Carlo algorithm. We 
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show that this mixture modelling approach generally produces higher estimates of 
the proportion previously infected than the standard threshold analysis. 
 
Results 
We found that the positive (previously infected) and negative (previously uninfected) 
distributions estimated from the mixture model did not segregate as clearly as 
expected based on the distributions observed in pre-COVID-19 and PCR-positive 
samples (Figure 1, Figure 2, Supplementary Table 1). In most surveys, this was 
because the positive distribution was shifted to the left relative to the distribution in 
PCR-positive samples, i.e. the mean was lower than in the PCR-positive samples 
(mean log2 OD ratios = 3.07). In contrast, the mean of the negative distribution was 
usually similar to the mean observed in the pre-COVID-19 samples (mean log2 OD 
ratios = -0.17). However, there was some variation by region, and in the surveys 
done in truck drivers the means were higher, while in the surveys done in pregnant 
women they were lower. In most surveys, the skew parameter of the positive 
distribution was close to zero, and the scale parameter, which determines the spread 
of the positive distribution, was similar to the standard deviation in PCR-confirmed 
cases (SD log2  OD ratios =1.32). 
 
Because the mixture model predicted lower antibody levels in previously infected 
individuals than was observed in the PCR-positive samples, the sensitivity of the 
threshold (i.e. the proportion of OD ratios > 2 in the positive component) was 
generally lower than assumed in the standard threshold-based analysis; 
consequently the mixture model analysis produced higher  estimates of the 
proportion previously infected than the threshold analysis (Figure 3, Supplementary 
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Figure 1 and Supplementary Table 2).  Across all surveys the mean sensitivity was 
65% (cf. 93% sensitivity measured in the validation sample and assumed in the 
threshold analysis), and the estimated proportion previously infected was on average 
1.44-fold higher than in the threshold analysis.  
 
In general, the 95% credible intervals associated with the estimated proportions were 
wider in the mixture model analysis, with the largest differences occurring when 
there was strong overlap between the component distributions. For example, the 
three surveys of truck drivers (in Busia, Magarini and Malaba) produced the widest 
confidence intervals; they were also the surveys with the greatest overlap between 
the distributions. 
 
To assess the robustness of our results, we fitted an alternative model where log 
antibody levels follow a two-component mixture distribution in previously infected 
individuals and a normal distribution in previously uninfected individuals, as in the 
original model. The two positive components do not have a clear biological 
interpretation, nevertheless we might imagine that recent/symptomatic infections 
predominate in the high-antibody-level component and older/asymptomatic infections 
predominate in the low-antibody-level component. The predicted distributions and 
estimates of the proportion positive from this alternative model were similar to those 
from the original skew normal model suggesting that the results are not sensitive to 
the distribution assumed for the positive component (Supplementary Figure 2, 
Supplementary Figure 3). 
 
 6 
We further tested the mixture model in three simulated data scenarios 
(Supplementary Table 3). In scenario 1, the test data were generated by combining 
the PCR-positive and pre-COVID-19 samples. In scenarios 2 and 3 either the 
positive (scenario 2) or negative component (scenario 3) was simulated from a 
mixture of two normal distributions and the other component was simulated from a 
single normal distribution. 
 
In keeping with the results of the sensitivity analysis, the mixture model performed 
well in scenarios 1 and 2: in both cases the estimated proportion positive was close 
to the expected value (scenario 1: 15% vs 14%; scenario 2: 19% vs 20%). By 
contrast, in scenario 3— where a mixture was used for the negative component—the 
mixture model estimate was severely biased (estimated = 36%, expected = 20%). 
This bias arises because the variance for the negative component is fixed to be 
equal to the variance estimated from pre-COVID-19 samples (this is one of the 
constraints used to fit the model).  Consequently, variation that should be attributed 
to the negative component is instead attributed to the positive component thereby 
overestimating the proportion positive.   
 
The findings from scenario 3 suggest that combining data across different 
populations may lead to the overestimation of previous infection. To test this 
hypothesis, we conducted a Kenya-wide analysis by combing the blood donor data 
and fitting the mixture model to these combined data. Our expectation was that the 
proportion previously infected would be overestimated in this analysis because of the 
variation in background antibody levels observed in the region-specific analyses 
(Supplementary Table 1). Specifically, we hypothesised that the estimate from the 
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analysis of the combined data would be greater than average of the region-specific 
estimates, after weighting by the number of samples collected in each region. 
Consistent with this prediction, the estimate from the combined analysis was 44.3% 
whereas the average of region-specific analyses was only 18.9%. In fact, the 




The mixture model analysis suggests that antibody levels are higher in samples from 
recent PCR-confirmed cases than in samples from previously infected serosurvey 
participants. Because of this, threshold-based estimates—which rely on having an 
accurate sensitivity estimate—underestimate previous infection.  
 
There are two potential explanations for the higher antibody levels in recent PCR-
confirmed cases. First, PCR-confirmed cases are more likely to be symptomatic, and 
symptoms such as cough, fever, and severe disease (hospitalisation) are positively 
associated with higher antibody levels 8–12. Second, PCR testing is usually done 
soon after infection when antibody levels are high. In the PCR-positive samples used 
in our study, for example, the median time between symptom onset and blood 
sample collection was 21 days, which may have been ideal to capture the peak 
antibody response. By contrast, many survey participants will have been infected 
several months earlier and their antibody levels may have waned in the meantime. 
Antibody waning has been reported in a number of studies 8–11,13,14, and those that 
have specifically accounted for waning by assuming a constant rate of 
seroreversion—rather than by accounting for spectrum bias more generally as we 
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have done—have predicted a significant impact on seroprevalence estimates 10,15,16. 
In general, waning is greatest for anti-nucleocapsid antibodies, but it can also be 
significant for anti-spike protein antibodies. For example, in one study involving 
milder cases of infection the half-life of anti-spike antibodies was estimated to be just 
73 days 17.  
 
The mixture model results suggest variability in the background levels of anti-spike 
IgG between different populations. In addition to variation by region, we observed 
higher IgG levels in truck drivers and lower levels in pregnant women. This variation 
will bias the standard threshold analysis. For example, in a population with low 
background IgG levels, as observed in pregnant women, the specificity estimate will 
be too low, and the sensitivity estimate too high. The variation will also bias mixture 
model analyses if data are combined across different populations, as exemplified by 
the Kenya-wide analysis of blood donor data.  
 
The reasons for the variation in baseline IgG levels are unclear. It could simply 
reflect temporal variation in the laboratory procedures, though the negative control 
should guard against this bias. Alternatively, it could be related to differences 
between populations in exposure to infection and possibly also infective dose. 
Several studies of pre-COVID-19 antibody levels have reported variation between 
populations, with antibody levels generally being higher in African populations than 
non-African populations 18,19. Furthermore, anti-SARS-CoV-2 antibodies are known 
to cross-react with antibodies against other coronaviruses 20, and possibly also 
antibodies against dengue 21 and malaria 22, though the latter finding was not 
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confirmed in a more recent study 23. For pregnant women, it is possible that low 
antibody levels are a feature of immune environment in pregnancy 24.  
 
The major limitation of the mixture modelling approach is that it is sensitive to the 
variance assumed for the uninfected population. Ideally the variance estimate should 
come from the population being surveyed, but in practice it will often be necessary to 
use an estimate from a different population. For example, we used pre-COVID-19 
samples from blood donors in the Coast region to estimate the variance, but then 
used this estimate to analyse data from other regions and from other subgroups 
such as pregnant women. Another limitation of the mixture modelling approach is 
that it is necessary to assume models for the component distributions. In our 
analysis, we assumed log antibody concentrations follow a normal distribution in 
previously uninfected individuals and a skew normal in previously infected 
individuals. However, we believe these distributional assumptions are not a major 
concern. The data from pre-COVID-19 samples suggests that log antibody levels in 
individuals who have not been infected are approximately normally distributed. And 
although we were unable to determine the distribution in previously infected 
individuals, the sensitivity analysis involving an alternative model and the analysis of 
simulated data both suggest that our estimates are robust to misspecification of this 
distribution. Finally, we note that our analysis was limited to Kenyan serosurveys; in 
the future it will be important to explore using mixture models to analyse surveys that 
have been done elsewhere. 
 
We have shown that the threshold analysis produces estimates of the proportion 
previously infected that are likely to be biased downwards. While overestimating this  
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proportion can lead to complacency in the assessment of future COVID-19 waves, 
underestimating it can also have serious adverse consequences if it prolongs social 
restrictions unnecessarily. This is particularly relevant in low-and-middle-income 
countries where resumption of educational, social and economic activities is unlikely 
to be brought about by rapid dissemination of COVID-19 vaccines. Here we provide 
an alternative to the standard threshold analysis that does not require specific 
adjustments for waning and allows for differences between populations in 
background antibody levels. The approach makes assumptions about variation in 
background antibody levels that need to be validated locally, but until we have a 
better understanding of the spectrum of antibody concentrations by symptom 





The blood samples were collected in studies of Kenyan blood donors 4,25, healthcare 
workers 26, truck drivers/assistants 27 and pregnant women 28. Most surveys were 
done shortly before or during the early stages of the second wave of the epidemic in 
Kenya (Supplementary Figure 4). The protocols for these studies were approved by 
the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research 
Institute. The blood donors and health care workers provided written informed 
consent, and the truck drivers provided verbal consent. Surveillance of antenatal 
care attendees was conducted at the request of the Kenya Ministry of Health and 
consent was obtained from participating health facilities and the respective Counties. 
The surveillance involved analysis of anonymised residual blood volumes of samples 
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collected in antenatal care clinics. Approval to publish the results of the antenatal 
care surveillance was explicitly requested from and granted by Kenyatta National 
Hospital, University of Nairobi Ethics Review Committee (Protocol P327/06/2020) 
and the Kilifi County health management rapid response team and SERU. 
Enzyme-linked immunosorbent assay (ELISA) 
Across all serosurveys, the samples were tested for anti-SARS-CoV-2 IgG 
antibodies using an adaptation of the Krammer ELISA for whole length spike antigen 
29. Ratios of optical densities (OD) relative to a negative control were used to 
quantify the antibody concentrations. The assay was originally validated using 910 
pre-COVID-19 serum samples collected in 2018, all of which were collected from 
adults and children from the Coast region of the country, and samples from 174 
PCR-positive Kenyan adults, which were collected from patients admitted to 
Kenyatta National Hospital in Nairobi and their contacts (14 pre-symptomatic, 55 
symptomatic, 92 asymptomatic and 13 unknown). For the samples obtained from 
PCR-positive individuals, the median time between the PCR test and blood sample 
collection was 21 days (IQR: 15, 34). The validation was based on a threshold OD 
ratio of 2, and yielded sensitivity and specificity estimates of 92.7% and 99.0% 
respectively. In a WHO-sponsored international standardization study, the 




Both the threshold-based analysis and the mixture model analysis were done using 
the Rstan package (version 2.21.2) in R version 4.0.4 31,32. 
 
Sensitivity and specificity adjusted threshold analysis 
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We incorporated information on the sensitivity and specificity of the threshold by 
simultaneously modelling the serosurvey data and validation data. Specifically, we 
modelled counts of i) the number, 𝑦, of survey samples above the threshold OD ratio, 
ii) the number, 𝑥, of PCR-positive samples above the threshold and iii) the number, 
𝑧, of pre-COVID-19 samples below the threshold. In the model, the proportion above 
the threshold,  𝑝 , is a function of the proportion previously infected, 𝑝, and the 
sensitivity and specificity of the threshold. 
Model: 
𝑦 ∼ Binomial(𝑝 , 𝑁 .  
𝑥 ∼ Binomial(se,  𝑁se  
𝑧 ∼ Binomial(sp, 𝑁sp) 
𝑝 = se × 𝑝 + (1 − sp × (1 − 𝑝 . 
Priors: 
𝑝 ∼ Uniform(0, 1  
se ∼ Uniform(0, 1  
sp ∼ Uniform(0, 1 . 
Mixture model  
We fitted a two-component mixture model where individuals are classified according 
to whether or not they have experienced SARS-CoV-2 infection. We assumed that 
log2 OD ratios follow a skew normal among previously infected individuals 
(parameters: location = 𝜉, scale = 𝜔 and skew=𝛼) and a normal distribution among 
previously uninfected individuals (parameters: mean = 𝜃, standard deviation = 𝜈).  
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Model: 
(1 − 𝑝 × Normal(𝜃, 𝜈 +  𝑝 × Skew Normal(𝜉, 𝜔, 𝛼 , 
where 𝑝 = proportion previously infected. 
To make it easier to interpret the model parameters, we reparameterised the model 
in terms of the difference, 𝛿 , between the means of the two distributions: 
𝜉 = 𝜃 + 𝛿 − 𝜔√2/𝜋 𝛼√1+𝛼2 . 
Since mixture models can be difficult to fit when there is overlap of the component 
distributions, we used several constraints to facilitate parameter estimation. First, we 
fixed the standard deviation in the uninfected, 𝜈, to be equal to the standard 
deviation in the pre-COVID-19 samples. Second, we used an informative prior for 𝛿 
to constrain the difference in means—the prior puts 5% probability on the difference 
exceeding the difference between the mean in symptomatic PCR-positive cases 
(mean log2 OD ratios = 3.43) and the mean in pre-COVID-19 samples (mean log2 
OD ratios = -0.17). The prior for 𝛿 was also designed to avoid label switching by 
ensuring 𝛿 > 0. Finally, we used an informative prior for 𝛼 to rule out strong skew in 
either direction.  
Priors: 
𝜃 ∼ Normal(0, 10  
𝛿 ∼ Normal+(0, 1.83  
ln 𝜔 ∼ Normal(0, 10  
𝛼 ∼ Normal(0, 1  
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𝑝 ∼ Uniform(0, 1 . 
In addition to estimating the model parameters, we estimated the sensitivity and 
specificity at various threshold values.  The sensitivity corresponds to the proportion 
above the threshold in the skew normal distribution and the specificity corresponds 
to the proportion below the threshold in the normal distribution. Both quantities were 
estimated using the sample of parameter values drawn from the posterior 
distribution. 
An alternative specification of the mixture model  
As a sensitivity analysis, we fitted an alternative model where we assumed that the 
distribution among previously infected individuals follows a mixture distribution with 
mixing parameter 𝑞.  
Model: 
(1 − 𝑝 × Normal(𝜃1, 𝜈1 + 𝑝 𝑞 × Normal(𝜃2, 𝜈2 + (1 − 𝑞 × Normal(𝜃3, 𝜈3 . 
 
As with the skew-normal model, the model was reparameterised in terms of the 
difference in mean between the positive and negative component, that is we defined 
 𝜃1 =  𝑞𝜃2 + (1 − 𝑞 𝜃3 − 𝛿, where 𝛿 represents the difference between the means. 
 
The priors for 𝜈𝑖 (𝑖 = 2, 3  were chosen to ensure that these standard deviations are 
of similar magnitude to the standard deviation observed in PCR-positive individuals 
(SD log2 OD ratios = 1.32 = exp(0.28)) and we used the constraint 𝜃3 > 𝜃2  to avoid 
the problem of label switching and ensure the identifiability of these parameters. 
Priors: 
𝛿 ∼ Normal+(0, 1.83  
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𝜃𝑖 ∼ Normal(0, 10     𝑖 = 2, 3    𝜃3 > 𝜃2 
ln 𝜈𝑖  ∼ Normal(0.28, 0.2       𝑖 = 2, 3 
𝑝 ∼ Uniform(0, 1  
𝑞 ∼ Uniform(0, 1 . 
Data Availability 
Source data are provided in the supplementary materials (xlsx file). 
 
Code Availability 
Stan code for fitting the Bayesian models is provided in Supplementary Notes 1-3 
and R/Stan code for all analyses, including the generation of tables and figures, is 





1. Abu-Raddad, L. J. et al. Assessment of the risk of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure 
setting. Clin. Infect. Dis. ciaa1846 (2020) doi:10.1093/cid/ciaa1846. 
2. Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in 
health care workers. N. Engl. J. Med. 384, 533–540 (2021). 
3. Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in 
Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 396, 
313–319 (2020). 
4. Uyoga, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan 
 16 
blood donors. Science 371, 79–82 (2021). 
5. Takahashi, S., Greenhouse, B. & Rodríguez-Barraquer, I. Are seroprevalence 
estimates for severe acute respiratory syndrome coronavirus 2 biased? J. 
Infect. Dis. 222, 1772–1775 (2020). 
6. Bouman, J. A., Riou, J., Bonhoeffer, S. & Regoes, R. R. Estimating the 
cumulative incidence of SARSCoV-2 with imperfect serological tests: 
Exploiting cutoff-free approaches. PLoS Comput. Biol. 17, e1008728 (2021). 
7. Gay, N. J. Analysis of serological surveys using mixture models: Application to 
a survey of parvovirus B19. Stat. Med. 15, 1567–1573 (1996). 
8. Lumley, S. F. et al. The duration, dynamics and determinants of SARS-CoV-2 
antibody responses in individual healthcare workers. Clin. Infect. Dis. ciab004 
(2021) doi:10.1093/cid/ciab004. 
9. Gaskell, K. M. et al. Extremely high SARS-CoV-2 seroprevalence in a strictly-
Orthodox Jewish community in the UK. medRxiv 2021.02.01.21250839 (2021) 
doi:10.1101/2021.02.01.21250839. 
10. Buss, L. F. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian 
Amazon during a largely unmitigated epidemic. Science 371, 288–292 (2021). 
11. Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses 
and duration of immunity: a longitudinal study. The Lancet Microbe 2, e240–
e249 (2021). 
12. Peluso, M. J. et al. SARS-CoV-2 antibody magnitude and detectability are 
driven by disease severity, timing, and assay. medRxiv 2021.03.03.21251639 
(2021) doi:10.1101/2021.03.03.21251639. 
13. Muecksch, F. et al. Longitudinal serological analysis and neutralizing antibody 
levels in coronavirus disease 2019 convalescent patients. J. Infect. Dis. 223, 
 17 
389–398 (2021). 
14. Figueiredo-Campos, P. et al. Seroprevalence of anti-SARS-CoV-2 antibodies 
in COVID-19 patients and healthy volunteers up to 6 months post disease 
onset. Eur. J. Immunol. 50, 2025–2040 (2020). 
15. Chen, S., Flegg, J. A., White, L. J. & Aguas, R. Levels of SARS-CoV-2 
population exposure are considerably higher than suggested by 
seroprevalence surveys. medRxiv 2021.01.08.21249432 (2021) 
doi:10.1101/2021.01.08.21249432. 
16. Brand, S. P. C. et al. COVID-19 transmission dynamics underlying epidemic 
waves in Kenya. medRxiv 2021.06.17.21259100 (2021) 
doi:10.1101/2021.06.17.21259100. 
17. Ibarrondo, F. J. et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons 
with mild COVID-19. N. Engl. J. Med. 383, 1085–1087 (2020). 
18. Tso, F. Y. et al. High prevalence of pre-existing serological cross-reactivity 
against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 
sub-Saharan Africa. Int. J. Infect. Dis. 102, 577–583 (2021). 
19. Emmerich, P. et al. Limited specificity of commercially available SARS-CoV-2 
IgG ELISAs in serum samples of African origin. Trop. Med. Int. Heal. 26, 621–
631 (2021). 
20. Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in 
humans. Science 370, 1339–1343 (2020). 
21. Lustig, Y. et al. Potential antigenic cross-reactivity between severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses. Clin. 
Infect. Dis. ciaa1207 (2020) doi:10.1093/cid/ciaa1207. 
22. Yadouleton, A. et al. Limited specificity of serologic tests for SARS-CoV-2 
 18 
antibody detection, Benin. Emerg. Infect. Dis. 27, 233–237 (2021). 
23. Nkuba Ndaye, A. et al. Challenges in interpreting SARS-CoV-2 serological 
results in African countries. Lancet Glob. Heal. 9, e588–e589 (2021). 
24. Sherer, M. L. et al. Dysregulated immunity in SARS-CoV-2 infected pregnant 
women. medRxiv 2020.11.13.20231373 (2020) 
doi:10.1101/2020.11.13.20231373. 
25. Adetifa, I. M. O. et al. Temporal trends of SARS-CoV-2 seroprevalence during 
the first wave of the COVID-19 epidemic in Kenya. Nat. Commun. 12, 3966 
(2021). 
26. Etyang, A. O. et al. Seroprevalence of antibodies to SARS-CoV-2 among 
health care workers in Kenya. Clin. Infect. Dis. ciab346 (2021) 
doi:10.1093/cid/ciab346. 
27. Kagucia, E. W. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies 
among truck drivers and assistants in Kenya. medRxiv 2021.02.12.21251294 
(2021) doi:10.1101/2021.02.12.21251294. 
28. Lucinde, R. et al. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care 
clinics in two Kenyan referral hospitals. medRxiv 2021.02.05.21250735 (2021) 
doi:10.1101/2021.02.05.21250735. 
29. Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in 
humans. Nat. Med. 26, 1033–1036 (2020). 
30. Mattiuzzo, G., Bentley, E. M., Hassall, M. & Routley, S. Establishment of the 
WHO international standard and reference panel for anti-SARS-CoV-2 
antibody. https://www.who.int/publications/m/item/WHO-BS-2020.2403 (2020). 
31. Carpenter, B. et al. Stan: A probabilistic programming language. J. Stat. Softw. 
76, 1–32 (2017). 
 19 




We thank the serosurvey participants for their contribution to this research.  
This project was funded by the Wellcome Trust (grant numbers 220991/Z/20/Z, 
203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547) and by the 
Foreign Commonwealth and Development Office (FCDO) through the East Africa 
Research Fund (EARF/ITT/039). J. Anthony G. Scott is funded by a Wellcome Trust 
Senior Research Fellowship (214320). Christian Bottomley is funded through an 
award that is jointly funded by the UK Medical Research Council (MRC) and the UK 
Foreign, Commonwealth and Development Office (FCDO) under the MRC/FCDO 
Concordat agreement and is also part of the EDCTP2 programme supported by the 
European Union (MR/R010161/1). For the purpose of open access, the authors have 
applied a CC BY public copyright licence to any Author Accepted Manuscript version 
arising from this submission. This work is published with the permission of the 
Director of the Kenya Medical Research Insitute. 
 
Author Contributions 
Conceptualization: AS, CB 
Methodology: CB, MO, AS 
Investigation: SU, KG, EK, AE, DM, JG, HK, JN, IA, AA, GW 
Writing – original draft: CB 








Figure 1: Distribution of anti-spike IgG antibodies in PCR-positive samples and pre-
COVID-19 samples. The dotted line indicates the threshold (OD ratio > 2) used to 
define seropositivity. 
 
Figure 2: Mixture distributions fitted to anti-spike IgG antibody data collected in 
serological surveys of Kenyan blood donors, antenatal care (ANC) attendees, 
healthcare workers (HCW), and truck drivers. The red distribution represents 
predicted responses in individuals previously infected with SARS-CoV-2 and the blue 
distribution represents predicted responses in previously uninfected individuals. 
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 Uninfected  Infected   
 Mean  95% CI  Mean  95% CI Scale  95% CI Skew  95% CI Sensitivity  95% CI Specificity  95% CI 
Blood donors             
   Central -0.17 -0.24 , -0.11  1.76 0.76 , 2.79 1.70 1.00 , 2.67 0.11 -1.79 , 2.13 0.70 0.43 , 0.96 1 1 , 1 
   Coast -0.54 -0.60 , -0.48  1.05 0.70 , 1.43 1.34 1.02 , 1.79 0.45 -1.15 , 2.46 0.51 0.38 , 0.66 1 1 , 1 
   E.N. -0.16 -0.20 , -0.12  1.16 0.64 , 1.77 1.49 1.09 , 2.01 0.49 -1.35 , 2.59 0.54 0.36 , 0.76 1 1 , 1 
   Mombasa -0.72 -0.76 , -0.69  1.95 1.70 , 2.18 1.43 1.04 , 1.93 -0.96 -2.61 , 0.79 0.80 0.72 , 0.87 1 1 , 1 
   Nairobi -0.39 -0.46 , -0.33  1.71 1.37 , 2.05 1.47 1.16 , 1.95 0.30 -1.23 , 2.13 0.71 0.60 , 0.81 1 1 , 1 
   Nyanza -0.11 -0.15 , -0.06  1.21 0.74 , 1.71 1.50 1.10 , 1.93 1.24 -0.86 , 3.11 0.55 0.37 , 0.74 1 0.99 , 1 
   Rift Valley 0.07 0.03 , 0.11  2.33 1.68 , 2.97 1.68 1.18 , 2.38 0.27 -1.49 , 2.26 0.82 0.66 , 0.95 0.99 0.98 , 0.99 
   Western 0.08 -0.01 , 0.17  2.07 0.65 , 3.35 1.56 0.57 , 3.31 0.01 -1.89 , 2.01 0.78 0.42 , 1.00 0.99 0.98 , 0.99 
Antenatal care attendees            
   Kilifi, Oct -0.61 -0.67 , -0.55  0.55 -0.12 , 1.33 0.82 0.44 , 1.41 0.02 -0.96 , 1.00 0.30 0.07 , 0.70 1 1 , 1 
   Kilifi, Dec -0.25 -0.33 , -0.17  1.48 0.76 , 2.24 1.55 1.02 , 2.30 0.36 -1.53 , 2.36 0.64 0.42 , 0.87 1 1 , 1 
   Nairobi  -0.38 -0.58 , -0.19  1.37 1.09 , 1.64 1.26 0.98 , 1.63 0.72 -0.91 , 2.35 0.63 0.52 , 0.74 1 1 , 1 
Healthcare workers  
 
          
   Busia  0.11 0.06 , 0.16  2.22 1.53 , 2.88 1.62 1.12 , 2.35 0.18 -1.65 , 2.19 0.80 0.63 , 0.95 0.98 0.98 , 0.99 
   Kilifi  -0.09 -0.15 , -0.02  2.05 1.39 , 2.60 1.31 0.85 , 1.99 0.25 -1.54 , 2.21 0.82 0.61 , 0.97 1 0.99 , 1 
   Nairobi  -0.04 -0.33 , 0.24  1.17 0.86 , 1.49 1.43 1.13 , 1.87 0.50 -1.09 , 2.37 0.55 0.43 , 0.66 0.99 0.96 , 1 
Truck drivers  
 
          
   Busia  0.64 0.51 , 0.75  1.57 1.19 , 1.94 1.17 0.89 , 1.42 1.88 -0.11 , 3.42 0.73 0.54 , 0.91 0.8 0.73 , 0.88 
   Magarini 0.64 0.35 , 0.88  1.35 0.95 , 1.90 1.04 0.74 , 1.46 1.11 -0.93 , 2.85 0.64 0.45 , 0.88 0.79 0.61 , 0.94 




Supplementary Table 2: Estimates of the proportion previously infected. 
 
 
*Adjusted for sensitivity and specificity of the threshold (OD ratio > 2)
 N OD ratio > 2  Adjusted*  Mixture model 
Blood donors   %  % 95% CI  % 95% CI 
   Central 225 6.2  6.1 2.8 - 10.1  9.9 4.9 - 17.2 
   Coast 435 15.4  15.9 12.2 - 20.0  31.3 23.7 - 40.3 
   Eastern/ N. Eastern 702 6.0  5.5 3.5 - 7.6  12.2 7.5 – 19.0 
   Mombasa 802 16.7  17.2 14.3 - 20.3  22.6 19.3 - 26.1 
   Nairobi 361 23.5  24.8 20.1 - 29.8  35.7 28.9 - 42.9 
   Nyanza 584 9.4  9.3 6.7 - 12.1  17.6 11.4 - 26.8 
   Rift Valley 508 8.1  7.8 5.2 - 10.7  8.0 5.4 - 11.3 
   Western 106 5.7  6.0 1.8 - 11.7  7.3 2.4 - 15.1 
   All Regions 3,723 11.9  11.9 10.5 - 13.3  44.3 40.4 - 48.3 
Antenatal care attendees        
   Kilifi  264 1.1  0.9 0 - 2.8  5.9 1.7 - 12.9 
   Kilifi  155 10.3  10.7 5.9 - 16.5  16.3 9.2 - 25.4 
   Nairobi  196 46.4  49.8 42.0 - 57.8  75.5 63.8 - 87.4 
Healthcare workers        
   Busia  301 12.3  12.6 8.6 - 17.1  12.4 8.0 - 18.0 
   Kilifi  200 11.5  12.2 7.7 - 17.6  13.5 8.4 - 19.9 
   Nairobi  183 41.0  43.9 36.0 - 52.0  74.6 59.7 - 92.3 
Truck drivers        
   Busia  365 44.7  48.0 42.1 - 54.0  46.9 29.9 - 74.2 
   Magarini  101 42.6  45.6 35.1 - 56.3  50.9 20.3 - 91.3 





Supplementary Table 3: Three tests of the mixture model using data where the proportion previously infected is known. 
  
Data  Mixture model estimate  
Uninfected Infected % Infected  Uninfected Infected % Infected 
Test 1: PCR +ve (symptomatic and 
asymptomatic) and pre-COVID-19 
samples combined 
  
N = 910 
Mean = -0.17 
SD = 0.42 
N = 147 
Mean = 3.07 




Mean = -0.19  
Mean = 3.06 
Scale = 1.72 
Skew = -2.25 
 
15% 
Test 2: Mixture of distributions in 
previously infected individuals 
(simulated data) 
 
N = 200 
Mean = 0 
SD = 0.42 
N = 25, 25 
Mean = 2, 0.5 





Mean = -0.01 
 
Mean = 1.38 
Scale = 2.06 




Test 3: Mixture of distributions in 
previously uninfected individuals 
(simulated data) 
  
N = 100, 100 
Mean = -0.3, 0.3 
SD = 0.42, 0.42  
N = 50 
Mean = 1.4 





Mean = -0.03  
Mean = 0.86 
Scale = 1.67 
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Supplementary Figure 2: Antibody level distributions predicted by the three-
component mixture model (blue distribution = previously uninfected individuals, 
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Supplementary Figure 3: Estimates of the proportion previously infected (with 95% 












































Supplementary Figure 4: Timeline of serosurveys and cumulative COVID-19 cases 
in Kenya (March – December, 2020). 
 
 
TRU = truck drivers, ANC = antenatal clinic attendees, HCW = healthcare workers 







































  int N; 
  int N_se; 
  int N_sp; 
  int y; 
  int x; 




  real<lower=0,upper=1> p; 
  real<lower=0,upper=1> se; 
  real<lower=0,upper=1> sp; 
} 
 
transformed parameters { 
  real<lower=0,upper=1> p_obs; 




   y ~ binomial(N, p_obs); 
   x ~ binomial(N_se, se); 






























  int N; 




  real theta; 
  real<lower=0> delta; 
  real log_omega; 
  real alpha;                
  real<lower=0,upper=1> p; 
} 
 
transformed parameters { 
  real xi; 
  real nu = 0.42; 
  real<lower=0> omega; 
  real theta_delta; 
  omega = exp(log_omega); 
  theta_delta = theta + delta; 





  // priors 
  theta ~ normal(0, 10); 
  delta ~ normal(0, 1.83);  
  log_omega ~ normal(0, 10); 
  alpha ~ normal(0, 1); 
   
  //likelihood 
  for (n in 1:N) { 
    target += log_sum_exp(log(p) 
                           + skew_normal_lpdf(y[n] | xi, omega, alpha), 
                          log1m(p) 
                          + normal_lpdf(y[n] | theta, nu)); 
  } 
}   
   
generated quantities{ 
    vector[10] cut = [-2, -1.5, -1, -0.5, 0, 0.5, 1, 1.5, 2, 5]'; 
    vector[10] sp; 
    vector[10] se; 
    for (i in 1:10) { 
      sp[i] = exp(normal_lcdf(cut[i] | theta, nu)); 
      se[i] = exp(skew_normal_lccdf(cut[i] | xi, omega, alpha)); 












  int N; 
 
 




  ordered[2] thetaInf;  
  real<lower=0> delta;  
  vector<lower=0>[2] nuInf;  
  real<lower=0, upper=1> p; 




  vector[3] theta; 
  vector[3] nu; 
  vector[3] pr; 
  theta[1] = q * thetaInf[1] + (1 - q) * thetaInf[2] - delta; 
  theta[2] = thetaInf[1]; 
  theta[3] = thetaInf[2]; 
  nu[1] = 0.42; 
  nu[2] = nuInf[1]; 
  nu[3] = nuInf[2]; 
  pr[1] = 1 - p; 
  pr[2] = p * q; 





  vector[3] log_pr= log(pr); 
 
  // priors 
  thetaInf ~ normal(0, 10); 
  delta ~ normal(0, 1.83);  
  nuInf ~ lognormal(0.28, 0.2);  
   
  //likelihood 
  for (n in 1:N) { 
      vector[3] lps = log_pr;  
      for (k in 1:3){ 
        lps[k] += normal_lpdf(y[n] | theta[k], nu[k]); 
      } 
      target += log_sum_exp(lps); 
    } 
} 
 
 
 
 
